There are two subsets of Hematopoietic stem cells (HSC); one subset that provides balanced production of myeloid and lymphoid cells, and another that is biased toward production of the myeloid lineage.
Researchers at Stanford have discovered that nanobodies blocking amphiregulin (AREG) activity have the potential to impede the progression of early-stage atherosclerotic plaque lesions to advanced-stage fibroatheromas.